Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician

• Published in: Endocrine Vol. 52; no. 2; pp. 194 - 205
• Main Authors: Yuen, Kevin C. J., Heaney, Anthony P., Popovic, Vera
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.05.2016
• Subjects: Acromegaly - chemically induced; Animals; Contraindications; Diabetes; Endocrinology; Growth Hormone - administration & dosage; Growth Hormone - adverse effects; Hormone Replacement Therapy - adverse effects; Humanities and Social Sciences; Humans; Hypopituitarism - drug therapy; Insulin-Like Growth Factor I - deficiency; Internal Medicine; Medicine; Medicine & Public Health; multidisciplinary; Neoplasms - chemically induced; Receptors, Somatotropin - deficiency; Review; Science; Adults; Malignancy; Growth hormone; Growth hormone deficiency; Cancer
• ISSN: 1355-008X; 1559-0100
• DOI: 10.1007/s12020-015-0840-2

Previous studies have shown that GH and IGF-I may enhance tumorigenesis, metastasis, and cell proliferation in humans and animals. Evidence supporting this notion is derived from animal model studies, epidemiological studies, experience from patients with acromegaly, molecular therapeutic manipulation of GH and IGF-I actions, and individuals with GH receptor and congenital IGF-I deficiencies. Prior exposure to radiation therapy, aging, family history of cancer, and individual susceptibility may also contribute to increase this risk. Therefore, the use of GH replacement in patients with a history of cancer raises hypothetical safety concerns for patients, caregivers, and providers. Studies of GH therapy in GH-deficient adults with hypopituitarism and childhood cancer survivors have not convincingly demonstrated an increased cancer risk. Conversely, the risk of occurrence of a second neoplasm (SN) in childhood cancer survivors may be increased, with meningiomas being the most common tumor; however, this risk appears to decline over time. In light of these findings, if GH replacement is to be considered in patients with a previous history of cancer, we propose this consideration to be based on each individual circumstance and that such therapy should only be initiated at least 2 years after cancer remission is achieved with the understanding that in some patients (particularly those with childhood cancers), GH may potentially increase the risk of SNs. In addition, close surveillance should be undertaken working closely with the patient’s oncologist. More long-term data are thus needed to determine if GH replacement in GH-deficient adults with a history of cancer is associated with the development of de novo tumors and tumor recurrence.